AvaSure, Equum Medical Team Up on Telehealth Solution for the Nursing and Care Quality Crisis

Alliance of market leaders in virtual patient monitoring and clinical services looks to ease hospital staffing shortages and avert adverse events

AvaSure, the inventor of the TeleSitter® solution and the market leader in patient safety monitoring, and Equum Medical, a leading telehealth-enabled acute care professional clinical services company, today announced a new strategic partnership to help hospitals address the nurse staffing shortage and slow a sharp spike in adverse events in inpatient care.

Hospitals today are faced with the challenge of doing more with less. A recent study found that 30% of healthcare workers had quit or been laid off since the pandemic began, while 31% of the remaining workforce was thinking about finding another job. Prior to the pandemic, it was estimated that more than 1 million registered nurses would leave the workforce by 2030, most to retirement. With resourced care delivery at the bedside in jeopardy, adverse events are increasing, including patient falls. Nearly 1 million patient falls occur in healthcare settings, with a third being preventable, costing the U.S. healthcare system nearly $34 billion annually, studies show. With an aging population, hospital operating expenses rising, nurse safety and patient experience are at risk without the integration of new models that extend access to resources such as telehealth.

Working together, Equum and AvaSure will provide an affordable, easily adoptable and highly effective virtual monitoring solution. Equum will host monitoring services from its new Virtual Care Collaboration Center in Nashville. The service will utilize AvaSure’s hardware and software solutions, including a greater choice of room monitoring devices that provide uninterrupted uptime from thousands of hospital rooms across any geographic area.

“This partnership of telehealth leaders responds to customer demand for cost-effective solutions that make the most of increasingly scarce nursing resources,” said Lisbeth Votruba, MSN, RN, AvaSure’s chief innovation officer. “We want to free nurses to practice at the top of their license, providing clinical care instead of worrying constantly about fall-risk patients or responding to routine patient requests.”

This form of patient monitoring, in which highly trained patient safety specialists keep 24-7 watch via video and intervene via audio or alarms to stop risky behavior, comes amid a sudden rise in adverse events in hospitals nationwide, as exhausted hospital staff struggle just to keep COVID-19 patients alive.

“Equum has been helping hospitals with clinical expertise virtually for a number of years, so this is both a natural extension of our core telehealth services and a new way to address a worsening situation in patient safety,” said Corey Scurlock, MD, MBA, Equum’s CEO… “We look forward to broadening and deepening this offering to include specialist care and improve patient flow throughout the hospital.”  In August, growth funding by Heritage has enabled Equum Medical to further enhance its service model and broaden the reach of its experienced team of clinicians to support new telehealth care offerings such as TeleSitter.

The companies share a common commitment to patient safety and an approach to change management within organizations that is evident in the design of the partnership. They came together to help hospital systems that may not have had the funds in the past to implement a comprehensive TeleSitter program with all the elements to implement and manage care.

Scurlock and Votruba will discuss the nurse staffing crisis and the joint solution in a webinar on March 29th. You can register at avasure.com/event/avasure-equum-webinar. Additionally, members of the new venture team will be on hand at the American Organization for Nursing Leadership (AONL) Meeting April 11-14 in San Antonio to discuss the solution.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”